PO.ET08.03 · 实验与分子治疗
用于精准医学的创新型诊疗一体化Trop2抗体-放射性核素偶联物（ARCs）
Innovative theranostic Trop2 antibody-radionuclide conjugates (ARCs) for precision medicine
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
诊疗一体化抗体偶联物是一类新兴的治疗药物，它将抗体与既能诊断又能治疗疾病的放射性核素相结合。我们开发了一种位点特异性的Trop2抗体-放射性核素偶联物（ARC），其整合了用于成像的89Zr和用于治疗的225Ac。成像型ARC利用89Zr的长半衰期，在多种异种移植模型（包括三阴性乳腺癌和非小细胞肺癌）中表现出强烈的肿瘤蓄积和良好的肿瘤与正常组织（T/N）比值。携带α发射放射性核素的治疗型ARC，在相应的异种移植模型中有效抑制了肿瘤生长。该ARC目前处于临床前开发阶段，计划于2026年提交研究性新药（IND）申请。
查看英文原文 English abstract
Theranostic antibody conjugates are an emerging class of therapeutics that combines an antibody with radionuclides that can both diagnose and treat disease. We have developed a site-specific Trop2 antibody-radionuclide conjugate (ARC), incorporating 89Zr for imaging and 225Ac for therapy. The imaging ARC, leveraging the long half-life of 89Zr, demonstrates strong tumor accumulation and favorable tumor-to-normal tissue (T/N) ratios across multiple xenograft models, including triple-negative breast cancer and non-small cell lung cancer. The therapeutic ARC, carrying an alpha-emitting radionuclide, effectively suppresses tumor growth in the corresponding xenograft models. This ARC is currently in preclinical development, with an investigational new drug (IND) application planned for 2026.
利益披露 Disclosure
S. Chuang, None..
W. Sun, None..
H. Xu, None.